Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 69, Issue 4, 1998, Pages 691-696

  Morin Papunen, Laure C ^a   Koivunen, Riitta M ^a   Ruokonen, Aimo ^a   Martikainen, Hannu K ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Hyperinsulinemia; Insulin resistance; Metformin; PCOS

Indexed keywords

GONADOTROPIN; INSULIN; METFORMIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MENSTRUATION; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; ANDROSTENEDIONE; BLOOD GLUCOSE; COHORT STUDIES; DEHYDROEPIANDROSTERONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUTEINIZING HORMONE; MENSTRUATION; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS;

EID: 0031968394     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00011-9     Document Type: Article

References (25)

1. Franks S. Polycystic ovary syndrome a changing perspective . Clin Endocrinol (Oxf). 31:1989;87-120.
2. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
3. Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endrocrinol. 12:1994;15-20.
4. Burghen GA, Givens JR, Kibatchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary syndrome. J Clin Endrocrinol Metab. 50:1980;113-116.
5. Martikainen H, Salmela P, Nuojua-Huttunen S, Perälä J, Leinonen S, Knip M, et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertil Steril. 66:1996;564-570.
6. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinism. J Clin Endocrinol Metab. 65:1987;499-507.
7. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Lichola T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41:1992;1257-1266.
8. Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol (Oxf). 39:1993;623-632.
9. Slowinski-Szrendnicka J, Zgliczynski S, Wierzbicki M. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest. 14:1991;569-575.
10. Reaven GM. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
11. Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol. 12:1994;38-44.
12. Williams G. Management of non insulin-dependent diabetes mellitus. Lancet. 343:1994;95-100.
13. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenism, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
14. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab. 80:1995;2057-2062.
15. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet. 1:1988;870-872.
16. Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 11:1996;29-39.
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1961;1440-1447.
18. Robert Y, Dubrulle F, Gaillandre L, Ardaens Y, Thomas-Desrousseaux P, Lemaitre L, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders visual analysis versus computerized qualification . Fertil Steril. 64:1995;307-312.
19. Second report on diabetes mellitus. Tech Rep Ser 646. 1980;WHO, Geneva.
20. Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G. Endometrial carcinoma. Ovarian dysfunction - a risk factor in young women. Eur J Obstet Gynecol Reprod Biol. 41:1991;143-150.
21. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:1996;617-623.
22. Acbay Ö, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 65:1996;946-949.
23. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530.
24. Singh A, Hamilton-Fairley D, Koistinen R, Seppälä M, James VHT, Franks S, et al. Effect of insulin-like growth factor type I (IGF-I) and insulin on the secretion of sex hormone binding globulin and IGF-I binding protein (IGP-I) by human hepatoma cells. J Endocrinol. 124:1990;RI-III.
25. Nestler JE, Beer NA, Jakubowitcz DJ, Beer RM. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab. 78:1994;549-554.